Intellia Therapeutics Stock Forecast

Stock Price Forecast

According to 19 analysts polled by S&P Global, Intellia Therapeutics stock has a consensus rating of "Buy" and an average price target of $23.94. The average 1-year stock price forecast is 106.38% higher than the current stock price, while the lowest is $8.00 (-31.03%) and the highest is $61 (+425.86%).

Price Target: $23.94 (+106.38%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$8.00	$23.94	$17	$61
Change	-31.03%	+106.38%	+46.55%	+425.86%

Analyst Ratings

The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	13	13	11	10	8	9
Buy	1	1	1	2	1	1
Hold	9	9	9	8	7	6
Sell	1	1	1	1	1	1
Strong Sell	1	1	1	1	2	2
Total	25	25	23	22	19	19

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Debanjana Chatterjee JonesTrading	JonesTrading	Buy Maintains $29	Buy	Maintains	$29	+150.00%	Aug 14, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Hold Reiterates $15	Hold	Reiterates	$15	+29.31%	Aug 10, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Buy Maintains $49	Buy	Maintains	$49	+322.41%	Aug 7, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Sell Maintains $9	Sell	Maintains	$9	-22.41%	Aug 7, 2026
Jonathan Miller Evercore ISI	Evercore ISI	Buy Upgrades $16 → $24	Buy	Upgrades	$16 → $24	+106.90%	Aug 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

51.88M

from 67.67M

-23.33%

from 67.67M

Revenue Next Year

125.47M

from 51.88M

141.85%

from 51.88M

EPS This Year

-3.15

from -3.81

EPS Next Year

-2.60

from -3.15

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	33.05M	52.12M	36.28M	57.88M	67.67M	51.88M
Revenue Growth	-43.01%	57.69%	-30.40%	59.55%	16.92%	-23.33%
Operating Income	-267.85M	-458.16M	-515.29M	-534.26M	-440.99M	-434.20M
Net Income	-267.89M	-474.19M	-481.19M	-519.02M	-412.69M	-420.02M
EPS	-	-	-	-	-3.81	-3.15
Free Cash Flow	-69.57M	-256.18M	-268.21M	-133.38M	-233.29M	-404.15M
No. Analysts	-	-	-	-	-	17

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	100.0M
Avg	51.9M
Low	22.7M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	47.8%
Avg	-23.3%
Low	-66.4%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.71
Avg	-3.15
Low	-3.41

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-